

REMARKS

Entry of the foregoing and reexamination and reconsideration of the subject application, as amended, pursuant to and consistent with 37 C.F.R. § 1.112, are respectfully requested in light of the following remarks.

STATEMENT OF SUBSTANCE OF INTERVIEW

The courtesy of the telephone interview granted by Examiner Landau to the undersigned representative on February 15, 2008, is gratefully acknowledged.

The Examiner has correctly summarized the interview in the Interview Summary mailed March 3, 2008. Specifically, the Examiner indicated that the independent method claims would be allowable, including those previously withdrawn, if the structures of the compounds of dependent Claim 22 were incorporated into the independent claims. Further, the Examiner suggested removing the terms "derivatives" and "analogues" to obviate the 35 U.S.C. § 112, second paragraph issue and made other suggestions for clarifying the claims. Applicants thank the Examiner for her helpful suggestions as to what actions are needed to place this application in allowable form. The present amendment seeks to make those amendments so that this application can proceed to allowance.

STATUS OF CLAIMS

Upon entry of the foregoing amendment, Claims 1, 2, 4-7, 9-12, 21, 23, 36, 38-44, 46-49 and 53-60 will remain in this application. Claims 15, 16, 18-20 and 22 are cancelled by the present amendment, without prejudice or disclaimer. Claims 3, 8, 13-14, 17, 24-35, 37, 45 and 50-52 were cancelled previously.

DISCUSSION OF AMENDMENTS MADE

Claims 1, 2, 4, 5, 7, 9 and 10, which are independent method claims, have been amended to insert therein the specific compounds of Claim 22, in accord with the Examiner's indication that such claims would be allowable. Claim 22 has accordingly been cancelled as redundant. These amendments have been made solely to expedite prosecution of this application. Applicants reserve the right to pursue broader method claims, not limited to the seven compounds of Claim 22, in a continuing application.

Claims 15, 16, and 18-20 have been cancelled because the substituents there defined already have specific meanings in the seven compounds whose use is now encompassed by Claim 1.

Claim 21 has been amended to correct the Markush language. The scope is the same.

Claim 40 has been clarified as suggested by the Examiner. The scope is the same.

Claim 41 has been amended to recite a specific retinol derivative and a specific tocopherol derivative disclosed in the paragraph bridging pages 36 and 37 of the original specification. The references to "derivatives" have been removed as required by the Examiner.

Claim 43 has been amended to delete the words "derivatives" and "analogues" and to also make other minor clarifications.

Claim 53-56 have been amended to add punctuation.

Claim 58 has been amended to delete the reference to "derivatives."

It is clear from the foregoing that no new matter has been added.

It is believed that Applicants have complied with all of the Examiner's suggestions and that this application is now in condition for allowance. Further, favorable action in the form of a Notice of Allowance is believed to be next in order and is earnestly solicited.


If there is any problem with the quality of the present submission, the Examiner is asked to telephone the undersigned so that the amendment can be re-submitted. The Examiner is also requested to telephone the undersigned if there are any remaining matters which are in need of attention.

Respectfully submitted,

BUCHANAN INGERSOLL & ROONEY PC

Date: April 2, 2008

By:


Mary Katherine Baumeister
Registration No. 26254

P.O. Box 1404
Alexandria, VA 22313-1404
703 836 6620